Glaxo and Vir COVID-19 treatment meets endpoint in Phase III trial

0
80

A Phase III trial of intramuscular administration of sotrovimab met its primary endpoint of non-inferiority to intravenous administration for early treatement of COVID-19 in high-risk adults and adolescents, GlaxoSmithKline GSK, +0.12% GSK, +0.28% and Vir Biotechnology VIR, +2.54% said. The companies noted the trial was conducted during the height of the Delta variant in Florida. “We designed sotrovimab to stand up to the variants that we anticipated would occur, and these data demonstrate that sotrovimab administered via IV or IM could prove important in the fight against COVID-19 following authorisation,” said Vir CEO George Scangos. U.K.-listed Glaxo shares edged up 0.3% while Vir shares rose 4% in premarket trade.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Billions of dollars in infrastructure bill for charging could supercharge electric vehicle adoption
Next articleNeed to Know: This chart could force bubble doubters to rethink matters

LEAVE A REPLY

Please enter your comment!
Please enter your name here